Medtronic plc MDT recently presented a robust collection of new clinical and real-world data on its MiniMed 780G insulin pump system. The results were demonstrated at the 83rd American Diabetes ...

The CE mark also allows Medtronic’s automated insulin delivery system to be used during pregnancy and by children as young as two.

Medtronic's introduction of the MiniMed 780G continuous glucose monitoring system and acquisition of EOFlow Co. Ltd. could inspire growth, but will be subject to fierce competition.

DUBLIN, June 2, 2021 /CNW/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced real-world clinical outcomes for 4,120 individuals on the MiniMed™ 780G system, a ...

Two years after submitting the MiniMed 780G system for FDA approval, Medtronic finally secured the agency’s signoff to begin selling it in the U.S.

Medtronic presents new data on MiniMed™ 780G system on fixed meal dosing and real-world Time in Range across wide variety of users PR Newswire - Fri Jun 23, 2023 ...

The CE Mark allows this next-generation sensor to be integrated with either the MiniMed™ 780G insulin pump system or InPen, or for stand-alone continuous glucose monitoring (CGM) use.

At the same time, the company pointed to real-world 780G data from more than 26,400 users with Type 2 diabetes, showing a time below range of less than 1%. Medtronic said it is also working with ...

Medtronic recently received FDA approval for its MiniMed 780G system, which is an insulin pump that automatically adjusts and corrects type 1 diabetes patients’ glucose levels every five minutes.

The recent lifting of the warning letter in the U.S. allowed Medtronic to launch the 780G system domestically, resulting in a 30% growth in pump sales in the last quarter.

Unfortunately, just as the 780g launch has begun, the firm is still dealing with the lingering effects of other patients moving away from earlier generations of Medtronic pumps.